BRPI0515374A - métodos de tratamento de epileptogenêse e epilepsia - Google Patents

métodos de tratamento de epileptogenêse e epilepsia

Info

Publication number
BRPI0515374A
BRPI0515374A BRPI0515374-3A BRPI0515374A BRPI0515374A BR PI0515374 A BRPI0515374 A BR PI0515374A BR PI0515374 A BRPI0515374 A BR PI0515374A BR PI0515374 A BRPI0515374 A BR PI0515374A
Authority
BR
Brazil
Prior art keywords
group
phenyl
alkyl
epileptogenesis
epilepsy
Prior art date
Application number
BRPI0515374-3A
Other languages
English (en)
Inventor
Yong Moon Choi
Robert Gordon
Gerald P Novak
Carlos R Plata-Salaman
Roy E Twyman
H Steve White
Boyu Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0515374A publication Critical patent/BRPI0515374A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODOS DE TRATAMENTO DE EPILEPTOGENêSE E EPILEPSIA. A presente invenção refere-se a métodos para a prevenções, tratamento, inibição ou interrupção de epilepsia e epileptogenênese em um indivíduo compreendendo a administração ao indivíduo que necessita de uma quantidade terapeuticamente eficaz de um composto, selecionado do grupo que consiste na fórmula (I) e da Fórmula (II), ou um seu éster ou sal farmaceuticamente aceitável; Fórmula (I) Fórmula (II) em que fenila está substituída em X com um a cinco átomos de halogênio selecionados do grupo que consiste em flúor, cloro, bromo e iodo; e, R~ 1~, R~ 2~, R~ 3~, R~ 4~, R~ 5~ e R~ 6~ são independentemente selecionados do grupo que consiste em hidrogênio e C~ 1-C~ 4~ alquila; em que C~ 1~-C~ 4~ alquila está opcionalmente substituída por fenila (em que fenila está opcionalmente substituída por substituintes independentemente selecionados do grupo que consiste em halogênio, C~ 1~-C~ 4~ alquila, C~ 1~-C~ 4~ alcóxi, amino, nitro e ciano).
BRPI0515374-3A 2004-09-16 2005-09-15 métodos de tratamento de epileptogenêse e epilepsia BRPI0515374A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61027604P 2004-09-16 2004-09-16
US69862505P 2005-07-12 2005-07-12
US70724205P 2005-08-11 2005-08-11
PCT/US2005/032861 WO2006033947A2 (en) 2004-09-16 2005-09-15 Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy

Publications (1)

Publication Number Publication Date
BRPI0515374A true BRPI0515374A (pt) 2008-07-22

Family

ID=36087909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515374-3A BRPI0515374A (pt) 2004-09-16 2005-09-15 métodos de tratamento de epileptogenêse e epilepsia

Country Status (23)

Country Link
US (2) US20060194873A1 (pt)
JP (1) JP2008513466A (pt)
KR (1) KR20070057939A (pt)
CN (1) CN101056629B (pt)
AT (1) ATE464044T1 (pt)
AU (1) AU2005287174B2 (pt)
BR (1) BRPI0515374A (pt)
CA (1) CA2580640A1 (pt)
CO (1) CO6382111A2 (pt)
CR (1) CR9053A (pt)
DE (1) DE602005020667D1 (pt)
DK (1) DK1809273T3 (pt)
EA (1) EA200700642A1 (pt)
ES (1) ES2342185T3 (pt)
HK (1) HK1105583A1 (pt)
HR (1) HRP20100304T1 (pt)
IL (1) IL181910A0 (pt)
MX (1) MX2007003278A (pt)
NO (1) NO20071921L (pt)
NZ (1) NZ553813A (pt)
PT (1) PT1809273E (pt)
RS (1) RS51269B (pt)
WO (1) WO2006033947A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517407A (en) * 1999-08-10 2003-10-31 Uab Research Foundation Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
CA2584854A1 (en) * 2004-10-15 2006-04-27 Janssen Pharmaceutica N.V. Carbamate compounds for use in treating neurodegenerative disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
WO2008045391A2 (en) * 2006-10-06 2008-04-17 Janssen Pharmaceutica Nv Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
CA2667909A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013100566A1 (en) * 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
JP6200527B2 (ja) * 2013-03-12 2017-09-20 バイオ−ファーム ソリューションズ カンパニー リミテッド 神経保護用フェニルカルバメート化合物及びこれを含む組成物
JP6807941B2 (ja) * 2016-02-29 2021-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド スルファメート誘導体化合物、その製造方法および用途
CN106053510A (zh) * 2016-05-16 2016-10-26 山东省分析测试中心 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
DE60003791T2 (de) * 1999-02-09 2004-02-05 The University Of Virginia Alumni Patents Foundation Felbamat-derivate
ES2304969T3 (es) * 1999-07-26 2008-11-01 Sk Holdings Co., Ltd. Composiciones anticonvulsivas transnasales.
US6562867B2 (en) * 2001-02-27 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
NZ527989A (en) * 2001-02-27 2005-12-23 Ortho Mcneil Pharm Inc Use of a halogenated 2-phenyl-1,2-ethanediol dicarbamate enantiomer or enantiomeric mixture wherein one enantiomer predominates for preventing or treating bipolar disorder
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen

Also Published As

Publication number Publication date
JP2008513466A (ja) 2008-05-01
WO2006033947A3 (en) 2006-06-29
ES2342185T3 (es) 2010-07-02
CN101056629A (zh) 2007-10-17
DE602005020667D1 (de) 2010-05-27
PT1809273E (pt) 2010-05-10
RS51269B (sr) 2010-12-31
CO6382111A2 (es) 2012-02-15
AU2005287174B2 (en) 2012-01-12
NZ553813A (en) 2010-09-30
US20060194873A1 (en) 2006-08-31
AU2005287174A1 (en) 2006-03-30
EA200700642A1 (ru) 2007-10-26
IL181910A0 (en) 2007-07-04
US20110152362A1 (en) 2011-06-23
CN101056629B (zh) 2012-01-11
CA2580640A1 (en) 2006-03-30
ATE464044T1 (de) 2010-04-15
HK1105583A1 (en) 2008-02-22
NO20071921L (no) 2007-06-12
CR9053A (es) 2009-10-30
MX2007003278A (es) 2007-10-08
WO2006033947A2 (en) 2006-03-30
DK1809273T3 (da) 2010-08-02
KR20070057939A (ko) 2007-06-07
HRP20100304T1 (hr) 2010-09-30

Similar Documents

Publication Publication Date Title
BRPI0515374A (pt) métodos de tratamento de epileptogenêse e epilepsia
WO2007008562A3 (en) Carbamate compounds for use in treating neurodegenerative disorders
TW200744575A (en) Methods of treating epileptogenesis
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
DK1408953T3 (da) Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom
RS67603A (en) Carbamate compounds for use in the treatment of pain
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
DE60210960D1 (de) Carbamat-verbindungen zur prävention oder behandlung von angstzuständen
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
TW200701978A (en) Methods of treating epileptogenesis and epilepsy
HK1063435A1 (en) Carbamate compounds for use in preventing or treating neuropathic pain
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.